Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and ...

A milestone was reached in the fight against HIV/AIDS with the development of Lenacapavir, a new injectable drug that ...

The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...

A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice ...

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

Lenacapavir, approved by the US FDA, presents a groundbreaking advancement in the battle against HIV. Developed by Gilead ...

Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these ...

WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable ...

The diagnosed prevalent cases of human immunodeficiency virus (HIV) are projected to increase globally at an annual growth r ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...

(Yicai) Jan. 3 -- US pharmaceutical company Gilead Sciences has been given the greenlight by Chinese regulators to sell its ...

Global partners have supported Africa’s progress in HIV vaccine research and development. Organisations such as the US ...